Muraglitazar
Muraglitazar (proposed tradename Pargluva) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ. The drug had completed phase III clinical trials, however in May, 2006 Bristol-Myers Squibb announced that it had discontinued further development. Data on muraglitazar is relatively sparse due to the recent introduction of this agent. One double-blind randomized clinical trial comparing muraglitazar and pioglitazone found that the effects of the former were favourable in terms of HDL-C increase, decrease in total cholesterol, apolipoprotein B, triglycerides and a greater reduction in HbA1c ( ''p'' <0.0001 for all comparisons). However, the muraglitazar group had a higher all-cause mortality, greater incidence of and